BMRN vs. UTHR, ALNY, IONS, MDGL, ALKS, BGNE, VTRS, SRPT, RDY, and TEVA
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include United Therapeutics (UTHR), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), BeiGene (BGNE), Viatris (VTRS), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical preparations" industry.
BioMarin Pharmaceutical (NASDAQ:BMRN) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.
In the previous week, BioMarin Pharmaceutical had 18 more articles in the media than United Therapeutics. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 16 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.86 beat BioMarin Pharmaceutical's score of 0.24 indicating that United Therapeutics is being referred to more favorably in the news media.
United Therapeutics has a net margin of 42.05% compared to BioMarin Pharmaceutical's net margin of 8.31%. United Therapeutics' return on equity of 18.72% beat BioMarin Pharmaceutical's return on equity.
BioMarin Pharmaceutical has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
BioMarin Pharmaceutical presently has a consensus target price of $106.11, indicating a potential upside of 36.80%. United Therapeutics has a consensus target price of $308.78, indicating a potential upside of 12.59%. Given BioMarin Pharmaceutical's higher probable upside, research analysts plainly believe BioMarin Pharmaceutical is more favorable than United Therapeutics.
BioMarin Pharmaceutical received 966 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 74.70% of users gave BioMarin Pharmaceutical an outperform vote while only 61.71% of users gave United Therapeutics an outperform vote.
98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 1.9% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 12.5% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
United Therapeutics has lower revenue, but higher earnings than BioMarin Pharmaceutical. United Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
BioMarin Pharmaceutical and United Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get BioMarin Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical Competitors List
Related Companies and Tools
